Changing strategies for target therapy in gastric cancer

Suk Young Lee, Sang Cheul Oh

Research output: Contribution to journalArticlepeer-review

27 Citations (Scopus)

Abstract

In spite of a worldwide decrease in the incidence of gastric cancer, this malignancy still remains one of the leading causes of cancer mortality. Great efforts have been made to improve treatment outcomes in patients with metastatic gastric cancer, and the introduction of trastuzumab has greatly improved the overall survival. The trastuzumab treatment took its first step in opening the era of molecular targeted therapy, however several issues still need to be resolved to increase the efficacy of targeted therapy. Firstly, many patients with metastatic gastric cancer who receive trastuzumab in combination with chemotherapeutic agents develop resistance to the targeted therapy. Secondly, many clinical trials testing novel molecular targeted agents with demonstrated efficacy in other malignancies have failed to show benefit in patients with metastatic gastric cancer, suggesting the importance of the selection of appropriate indications according to molecular characteristics in application of targeted agents. Herein, we review the molecular targeted agents currently approved and in use, and clinical trials in patients with metastatic gastric cancer, and demonstrate the limitations and future direction in treatment of advanced gastric cancer.

Original languageEnglish
Pages (from-to)1179-1189
Number of pages11
JournalWorld Journal of Gastroenterology
Volume22
Issue number3
DOIs
Publication statusPublished - 2016 Jan 21

Keywords

  • Advanced gastric cancer
  • Chemotherapy
  • Signal pathway
  • Strategy
  • Target therapy

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Changing strategies for target therapy in gastric cancer'. Together they form a unique fingerprint.

Cite this